Nyhet från partner

Curasight’s CEO: “We will deliver key milestones in the next 12 months”

Nyhet från Biostock

Publicerad: 10 Jun 08:29

Curasight’s uPAR-based theranostics platform uses positron emission tomography (PET), often combined with computed tomography (PET/CT), to create detailed images of cancer biology.

This enables more precise diagnosis and treatment by visualizing tumor characteristics. Its diagnostic tool, uTRACE, uses a radioactive tracer that binds to the uPAR biomarker, which is overexpressed on cancer cells, enabling precise.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg

Läs hela artikeln hos Biostock

Börskollen

För dig med koll på börsen

Nyhet från partner

Curasight’s CEO: “We will deliver key milestones in the next 12 months”

Nyhetsbrev